1. Characteristic 1: a compound [1] of structural formula or a pharmaceutically acceptable salt； select x from the group including: (1) oxygen and (2) NH； select t from the group of CH, N and N-oxidation； or select from the group of CH, N and N-oxidation； V is selected from the CH, N and N-oxide groups, provided that 1 or 2 T, u and V are n or N-oxide； a is selected from the group consisting of: (1) arilo and (2) heterogeneous, where a is not replaced or replaced by one to five alternatives selected from r7491；B selected from the following groups: (1) arilo, (2) aril-o, (3) cyclo quilo c83231；(4) cycloalkyl C₃₋₆alkyl C₁₋₁₀,(5) C₃₋₆-cycloalkyl C₁₋₁₀-O, (6) C₂₋₅-cycloheteroalkyl,(7) heteroaryl, (8) heteroaryl-O, (9) C alquilar-alkylaryl,and (10) heteroarylalkyl C₁₋₁₀；b. Not replaced or replaced by 1 to 5 substitutes selected from r7495；R1 was selected from: (1) halogen, (2) - or 74977 group；(3) -CN (4) alquilo Cy (5) cicloalquilo Cwherein each C₁₋₆-alkyl and C₃₋₆-cycloalkyl is unsubstituted or substituted with from one to three substituents chosen from Rⁱ；R² is chosen from the group consisting of: (1) hydrogen, (2) C₁₋₆ alkyl,y (3) cicloalquilo Cwherein each C₁₋₆-alkyl and C₃₋₆-cycloalkyl is unsubstituted or substituted with from one to three substituents chosen from Rʲ；R 3: selected from the group of (1) hydrogen, (2) halogen, (3) - or 74977；(4) C₁₋₆ alkyl,(5) alquenilo C(6) C83223 asphalt；y (7) cicloalquilo Cin which each C₁₋₆ alkyl,C₂₋₆ alkenyl,C₂₋₆ alkynyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with one to three substituents chosen from RL； R⁴ is chosen from the group consisting of: (1) hydrogen, (2) halogen, (3) -ORᵉ,(4) C₁₋₆ alkyl,(5) alquenilo C(6) C83223 asphalt；y (7) cicloalquilo Cin which each C₁₋₆ alkyl,C₂₋₆ alkenyl,C₂₋₆ alkynyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with one to three substituents chosen from RL； R⁵ is chosen from the group consisting of: (1) hydrogen, (2) C₁₋₃ alkyl, and (3) halogen； R⁶ is chosen from the group co
